tiprankstipranks
Trending News
More News >
C4 Therapeutics (CCCC)
NASDAQ:CCCC
US Market
Advertisement

C4 Therapeutics (CCCC) AI Stock Analysis

Compare
577 Followers

Top Page

CCCC

C4 Therapeutics

(NASDAQ:CCCC)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
$2.50
▲(2.04% Upside)
C4 Therapeutics' stock score is primarily impacted by its financial performance, which is weighed down by persistent losses and cash flow challenges. Technical analysis shows mixed signals, with no strong momentum in either direction. The valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a lower overall stock score.
Positive Factors
Proprietary Technology
C4 Therapeutics' proprietary protein degradation technology positions it as a leader in innovative cancer treatments, offering a competitive edge in the biopharmaceutical sector.
Revenue Growth
The company demonstrates strong revenue growth, indicating successful partnerships and increasing adoption of its technology, which supports long-term business expansion.
Strategic Partnerships
Strategic partnerships provide a stable revenue stream and validate the company's technology, enhancing its market position and potential for future growth.
Negative Factors
Profitability Challenges
Ongoing losses and negative cash flows highlight operational inefficiencies, posing a risk to financial stability and requiring strategic adjustments for sustainable growth.
Negative Cash Flow
Negative cash flows indicate challenges in cash generation, which can strain financial resources and limit the company's ability to invest in growth initiatives.
Margin Sustainability
Negative margins reflect cost management issues, impacting profitability and necessitating improvements to achieve financial health and competitive advantage.

C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)

C4 Therapeutics Business Overview & Revenue Model

Company DescriptionC4 Therapeutics (CCCC) is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat cancer and other diseases. The company operates within the biopharmaceutical sector, leveraging its proprietary platform to create a pipeline of drug candidates designed to selectively degrade disease-causing proteins. C4 Therapeutics aims to address unmet medical needs by providing more effective and safer treatment options for patients with various types of cancer.
How the Company Makes MoneyC4 Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that seek to leverage its proprietary protein degradation technology. The company may receive upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on sales of products developed through these collaborations. Additionally, C4 Therapeutics may engage in grant funding or government contracts to support research and development efforts. The success of its revenue model is heavily reliant on the advancement of its drug candidates through clinical trials and their eventual commercialization in partnership with established pharmaceutical companies.

C4 Therapeutics Financial Statement Overview

Summary
C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.
Income Statement
42
Neutral
The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.
Balance Sheet
55
Neutral
The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.
Cash Flow
48
Neutral
Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue34.24M35.58M20.76M31.10M45.78M33.20M
Gross Profit30.42M35.58M13.02M23.52M42.88M-45.24M
EBITDA-112.50M-103.37M-122.10M-124.28M-78.84M-62.89M
Net Income-111.58M-105.32M-132.49M-128.18M-83.89M-66.33M
Balance Sheet
Total Assets296.53M349.60M376.45M430.84M506.76M400.14M
Cash, Cash Equivalents and Short-Term Investments214.55M244.90M253.68M276.15M309.28M371.69M
Total Debt62.92M65.76M70.98M87.15M42.88M22.92M
Total Liabilities122.46M133.62M130.34M141.61M117.16M119.35M
Stockholders Equity174.06M215.99M246.11M289.23M389.61M280.79M
Cash Flow
Free Cash Flow-87.58M-65.34M-108.55M-111.44M-88.24M-67.90M
Operating Cash Flow-87.41M-65.16M-106.84M-105.94M-86.97M-67.25M
Investing Cash Flow81.88M-51.27M158.35M58.42M-189.34M-190.50M
Financing Cash Flow10.57M45.34M45.49M1.15M171.40M348.93M

C4 Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.45
Price Trends
50DMA
2.55
Negative
100DMA
2.23
Positive
200DMA
2.24
Positive
Market Momentum
MACD
-0.03
Negative
RSI
51.61
Neutral
STOCH
45.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.45 is above the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.55, and above the 200-day MA of 2.24, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 45.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.

C4 Therapeutics Risk Analysis

C4 Therapeutics disclosed 74 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

C4 Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$221.50M-52.99%16.55%16.73%
43
Neutral
$248.91M-180.71%64.43%
42
Neutral
$156.27M-2.25-100.00%66.57%
35
Underperform
$208.39M-16.20%
33
Underperform
$138.01M-406.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCCC
C4 Therapeutics
2.45
-3.55
-59.17%
SLS
SELLAS Life Sciences Group
1.99
0.77
63.11%
MCRB
Seres Therapeutics
17.85
3.85
27.50%
ELDN
Eledon Pharmaceuticals
3.48
0.11
3.26%
TVGN
Tevogen Bio Holdings
0.67
-2.07
-75.55%
ACTU
Actuate Therapeutics, Inc.
7.20
-2.03
-21.99%

C4 Therapeutics Corporate Events

Private Placements and Financing
C4 Therapeutics Announces Stock and Warrants Offering
Positive
Oct 16, 2025

On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
C4 Therapeutics Presents Phase 1 Trial Data
Neutral
Oct 16, 2025

On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
C4 Therapeutics Partners with Pfizer for Clinical Trial
Positive
Oct 1, 2025

On October 1, 2025, C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer. Under this agreement, Pfizer will provide elranatamab, a BCMAxCD3 bispecific antibody, at no cost for C4T’s upcoming Phase 1b trial. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab for treating relapsed/refractory multiple myeloma. The collaboration aims to establish an optimal dose for this combination therapy, potentially improving outcomes for multiple myeloma patients.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
C4 Therapeutics Reports Promising Phase 1 Trial Results
Positive
Sep 22, 2025

On September 20, 2025, C4 Therapeutics announced data from its Phase 1 clinical trial of cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma. The trial showed promising results with a 50% overall response rate at the highest dose level and a differentiated safety profile, supporting further development for potential accelerated approval. The company plans to initiate Phase 2 and Phase 1b studies in 2026, aiming to position cemsidomide as a class-leading treatment option.

The most recent analyst rating on (CCCC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Reports Q2 2025 Financial Results
Aug 8, 2025

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines through targeted protein degradation, primarily in the oncology sector. The company leverages its proprietary TORPEDO platform to advance its research and development efforts.

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
C4 Therapeutics Completes Phase 1 Trial Enrollment
Neutral
Aug 7, 2025

On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025